Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia.
A 47-year-old woman was diagnosed with acute myelomonocytic leukemia (AMMoL) and was treated with combination chemotherapy. After one cycle of remission induction therapy, she entered into complete remission and then received three cycles of consolidation therapy. A month after the last consolidation therapy, she was diagnosed with having the complication of chemotherapy-related HUS (C-HUS). The C-HUS improved after initiation of plasma exchange and antiplatelet therapy. In the present case, it seems that the antileukemic agents might play an important role in the development of C-HUS.
Okumura
H
H
Third Department of Internal Medicine, Kanazawa University School of Medicine, Ishikawa, Japan.
Nakamura
S
S
Ohtake
S
S
Yoshida
T
T
Kobayashi
K
K
Okabe
Y
Y
Matano
S
S
Kyohda
K
K
Matsuda
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology*; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D010951:Plasma Exchange; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D009353:Zinostatin / Q000008:administration & dosage
D010975:Platelet Aggregation Inhibitors; D003561:Cytarabine; D005047:Etoposide; D009353:Zinostatin; D011239:Prednisolone; C015019:enocitabine; D008942:Mitoxantrone; D003630:Daunorubicin